SIRT for Potentially Resectable HCC

Inclusion Criteria: HCC with diagnosis confirmed pathologically or clinically No pervious treatment for HCC At least one measurable intrahepatic target lesion Potentially resectable HCC: tumor(s) confined to the left/right hemiliver, with/without invasion to the unilateral branch of the portal vein and/or hepatic vein Disease amenable to SIRT (after evaluation) Child-Pugh Class A or without cirrhosis Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA<10^3 IU/mL Patients with hepatitis C need to finish the anti-HCV treatment Adequate organ and bone marrow function; the blood biochemical examination: platelet count ≥75×10^9/L, white blood cell count >3.0×10^9/L, absolute value of neutrophils >1.5×10^9/L, hemoglobin ≥85 g/L, ASL and AST≤5×ULN, creatinine≤1.5×ULN, INR<1.5 or PT/APTT normal range Life expectancy of at least 6 months Exclusion Criteria: Tumor involving main portal vein, bilateral branches of portal vein, or vena cava tumor extention beyond one lobe of the liver Bilobar tumor distribution Extrahepatic metastasis Decompensated liver function, including ascites, bleeding from esophageal and gastric varices, and/or hepatic encephalopathy Organ (heart, kidney) dysfunction HBsAg and anti-HCV antibody positive concurrently History of malignancy other than HCC Uncontrolled infection History of HIV History of organ and cell transplantation Patients with bleeding tendency